Table 1.

Demographic and clinical characteristics of the study cohort

	No Postdischarge Respiratory Disease (n = 189)	Postdischarge Respiratory Disease (n = 348)
Male	80 (42.3)	188 (54.0)
Race
White	131 (69.3)	194 (55.7)
Black/African American	47 (24.9)	138 (39.7)
Asian	8 (4.2)	4 (1.1)
Others	3 (1.6)	12 (3.4)
Gestational age, wk	27.0 (1.3)	26.8 (1.4)
Multiple births	63 (33.3)	76 (21.8)
Twins, n	52	66
Triplets or quadruplets, n	11	10
Birth weight, g, mean (SD)	972.5 (232.9)	933.3 (225.2)
PMA at test, wk, mean (SD)	37.1 (1.8)	37.5 (2.0)
Weight at test, g, mean (SD)	2,491.0 (462.6)	2,504.5 (486.5)
Level of support at test
No respiratory support	152 (80.4)	190 (54.6)
Nasal cannula ≤ 1 L/min	37 (19.6)	158 (45.4)
Nasogastric tube in place during test	42 (22.2)	63 (18.1)
On caffeine during test	6/180 (3.3)	12/326 (3.7)
BPD (modified Shennan)	50/188 (26.6)	145/342 (42.4)
PMA at discharge, wk, mean (SD)	38.8 (2.9)	39.7 (3.8)
Hospitalizations in Year 1
0	173/185 (93.5)	220/335 (65.7)
1	11/185 (5.9)	74/335 (22.1)
≥2	1/185 (0.5)	41/335 (12.2)
Symptom in Year 1
Frequent wheeze or cough, with inhaled steroids, for ≥6 mo	0	33/343 (9.6)
Frequent wheeze or cough for ≥6 mo	0	244/343 (71.1)
None	187/187 (100.0)	66/343 (19.2)
Medication use in Year 1
System steroids or pulmonary vasodilator	8/189 (4.2)	76/345 (22.0)
Inhaled steroids bronchodilator	6/189 (3.2)	118/345 (34.2)
None	175/189 (92.6)	151/345 (43.8)
Technology use in Year 1
Home oxygen after Month 6 or mechanical ventilation	1/189 (0.5)	61/344 (17.7)
Home oxygen use at Month 3 or tracheostomy	13/189 (6.9)	53/344 (15.4)
None	175/189 (92.6)	230/344 (66.9)

Definition of abbreviations: BPD = bronchopulmonary dysplasia; PMA = postmenstrual age; SD = standard deviation.

Data presented as n (%) unless otherwise noted.